StockData
Greenland Mines Ltd logo

Greenland Mines Ltd (GRML) stock

GRMLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as GRMLW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/30
$2.99+0.08 (+2.75%)

Close on Nov 20, 2026Market cap $40.92MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$40.92M
P/E ratio
–
Price to sales
–
Price to book
0.30
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$32.96M
EPS, diluted
-$10.78
Book value per share
$25.07
Diluted shares
5M

Trading

Previous close
$2.91
Open
$2.90
Day's range
$2.75 – $3.10
Volume
870,101
Average volume (20 days)
725,072
Beta (5 years)
0.95
52-week range
$2.75 – $36.99
RSI (14 days)
33.1
Volatility (1 year)
284.7%
Relative volume
0.14×
WACC
9.8%

Market cap history

Month-end market cap since 2022, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 20, 2026. The S&P 500 is measured by the SPY fund.

PeriodGRMLS&P 500DifferenceGRML per yearS&P 500 per year
1 month-51.8%-10.3%−41.5 pts
3 months-64.0%-9.3%−54.7 pts
Year to date-79.3%+1.9%−81.3 pts
1 year-85.1%+6.9%−92.0 pts
3 years-99.4%+57.5%−156.9 pts-82.3%+16.3%

Five years at a glance

Fiscal years 2021 to 2025 and trailing twelve months, USD

Operating income

-$29.23M

Net income

-$32.96M

EPS, diluted

–
Reported periodTrailing twelve months

Press releases

Releases Greenland Mines filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Greenland Mines

Biological Products, (No Diagnostic Substances)

Greenland Mines Ltd, previously known as Klotho Neurosciences, Inc., is a biotechnology company focused on developing treatments for chronic illnesses, including neurodegenerative conditions, cancer, and cardiovascular diseases. Its product pipeline centers on proprietary gene and cell therapy candidates, specifically KLTO-101 for Alzheimer's disease and KLTO-202 for amyotrophic lateral sclerosis, which utilize the Klotho protein. Additionally, the company maintains licensed platforms comprising generic pharmaceuticals and biosimilar biologics targeting various solid tumors, and it operates an initiative focused on exploring and mining critical and precious minerals. Its therapeutics target adult and pediatric patient populations suffering from severe chronic disorders.

Company profile, executives and history

Greenland Mines stock: common questions

What is Greenland Mines's stock price?

GRML closed at $2.99 on Nov 20, 2026, up 2.75% on the day. Over the past 52 weeks it traded between $2.75 and $36.99.

What is Greenland Mines's market cap?

Greenland Mines was worth $40.92M at the close on Nov 20, 2026: the share price times the diluted shares outstanding.

What is GRML's P/E ratio?

Greenland Mines lost money over fiscal 2025 (diluted EPS -$10.78), so it has no meaningful P/E ratio.

Does Greenland Mines pay a dividend?

No. Greenland Mines has not paid a cash dividend over the last twelve months.

How has GRML stock performed over the past year?

Including dividends, GRML returned -85.1% over the past year, against +6.9% for the S&P 500.

Who are Greenland Mines's competitors?

Companies most similar to Greenland Mines by business, industry and size include PASG, INMB, VYGR, MGTX, SGMOQ.

See a number that looks wrong?